Skip to main content
. Author manuscript; available in PMC: 2021 Feb 4.
Published in final edited form as: Structure. 2019 Dec 3;28(2):223–235.e2. doi: 10.1016/j.str.2019.11.007

Figure 5.

Figure 5.

Druggability scores (DSs) of unliganded structures of proteins with a cryptic site that is frequently well formed. The ligand bound at the cryptic site is shown in the label and is listed in parenthesis here. The distributions of DS values are shown in dark, light, and medium blue, respectively, for unbound structures, complexes, and mutants. A. Bovine beta-lactoglobulin (retinol). B. Thrombin (active site inhibitor 121). C. Integrin lymphocyte function-associated antigen-1 (LFA-1) ligand binding (I) domain (inhibitor BQM). D. Glutamate receptor 2 (competitive antagonist ATPO binding to the core of the receptor). \